WO1994019696A1 - Procede pour mettre en evidence l'affinite du fibrinogene et de ses derives aux formes filamentaires de levures, utilisation dans le domaine de la determination des levures pathogenes notamment en hemoculture - Google Patents
Procede pour mettre en evidence l'affinite du fibrinogene et de ses derives aux formes filamentaires de levures, utilisation dans le domaine de la determination des levures pathogenes notamment en hemoculture Download PDFInfo
- Publication number
- WO1994019696A1 WO1994019696A1 PCT/FR1993/000180 FR9300180W WO9419696A1 WO 1994019696 A1 WO1994019696 A1 WO 1994019696A1 FR 9300180 W FR9300180 W FR 9300180W WO 9419696 A1 WO9419696 A1 WO 9419696A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substance
- yeasts
- forms
- filamentary
- yeast
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56961—Plant cells or fungi
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/37—Assays involving biological materials from specific organisms or of a specific nature from fungi
- G01N2333/39—Assays involving biological materials from specific organisms or of a specific nature from fungi from yeasts
- G01N2333/40—Assays involving biological materials from specific organisms or of a specific nature from fungi from yeasts from Candida
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/745—Assays involving non-enzymic blood coagulation factors
- G01N2333/75—Fibrin; Fibrinogen
Definitions
- the present invention relates to a new method for demonstrating 1 • affinity of fibrinogen and its derivatives [ie fibrin and FDP which include fibrinogen degradation products (FgDP) and fibrin degradation products (FnDP )] to filamentary forms of yeast.
- Candida albicans are those which are encountered most often in cases of candidiasis and that they represent approximately 50% of the cases of positive blood cultures; we also know that the strains of Candida glabrata (old nomenclature: Torulopsis glabrata) have become the second agent, in order of importance, of septicemia, and that strains of Candida tropica ' lily and Candida krusei are at the origin of the others cases of candidiasis encountered in pathology.
- infectious agents are also known which are also frequently isolated and which are constituted by strains of Trichosporon and Cryptococcus (in particular strains of Cryptococcus neoformans) whose incidence is increasing more and more in patients suffering from the syndrome of acquired immunodeficiency (AIDS).
- AIDS acquired immunodeficiency
- a new method is recommended to demonstrate the possible affinity of a substance (F) chosen from the group consisting of fibrinogen (Fg), fibrin
- this process may only include steps (2 °) to (4 °), step (1 °) being able to be suppressed when a sample containing yeasts is available, essentially consisting of blastospores with one concentration greater than or equal to 10 * yeasts / ml, and preferably at a concentration of not less than 10 5 yeasts / ml, and essentially devoid or depleted substance which may interfere in the adhéren- that o f said substance mechanism (F) said yeasts.
- the method according to the invention for demonstrating the possible affinity of a yeast strain is useful in determining the affinity of a substance (F) with respect to the filamentary forms of yeast strains in the therapeutic area in cli- human or veterinary, in the agricultural and food fields.
- a method for determining the pathogenic or non-pathogenic character of yeast strains to be tested, characterized in that it comprises
- FDP ethylenediaminotetraacetic acid
- FBF fibrinogen fixing factor (or fibrinogen fixing factor) [from English:” fibrino-gen-binding factor "; other French nomenclature: FFF]
- FDP product of degradation of fibrinogen or fibrin [other French nomenclature: PDF]; the expression FDP generally includes the specific degradation products of fibrinogen / fibrin, namely the fragments D, E, X and Y, on the one hand, and the overall degradation products of fibrinogen / fibrin, of somewhere else ; unless otherwise stated,
- Fn fibrin
- FnDP degradation products of fibrin [other French nomenclature: PDFn]
- GT germ tubes [in English: “germ-tubes”; other French nomenclature: TG]
- filamentary forms is understood here the whole constituted by the germinative forms, which are essentially constituted by the GTs, and the • filamentous forms, which are essentially constituted by PMy and My.
- strains of yeast which filament means all the strains which give GT, PMy and My, on the one hand, and strains which give rise to a pseudofilamentation, on the other hand.
- the BL multiplication medium and the fila ⁇ menting medium of said BL are devoid or essentially depleted of substance (s) which can interfere with said substance (F) during the production of the 'step (3 e ).
- substance (s) which can interfere with said substance (F) during the production of the 'step (3 e ).
- fibrinogen and its derivatives namely:
- interfering substances listed above or some of them may be present in whole blood or blood plasma, on the one hand, as well as in the yeast samples which have been taken, on the other hand.
- blood and plasma generally contain fibrinogen and, where appropriate, one or more of its derivatives, and in particular in pathological cases of inflammation proteins and / or anti (yeast) antibodies [in particular anti ( Candida) in cases of candidiasis]; and samples of yeast strains of the Candida family may contain an antifungal compound such as cycloheximide which inhibits most yeasts and in particular Candida with the exception of strains of Candida albicans and some strains of Candida zeylanoides (see for this purpose the French patent application No. 90 03 726 of March 23, 1990 of the plaintiff).
- interfering substance (s) is avoided in the nutrient medium for multiplying BLs and in the nu ⁇ tritive medium for filamentation of BLs already multiplied by means of the appropriate choice of said nutrient media. Furthermore, depending on the origin of the yeast sample to be tested, it may be imperative to dilute said sample to deplete it with interfering substance (s).
- the nutrient media for multiplication and lamentation can be liquid (ie aqueous media called homogeneous or monophasic) or heterogeneous (ie aqueous media containing one or more solids and said two-phase).
- Multiplication and fila ⁇ mentation can be carried out aerobically or anaerobically.
- Preferred according to the invention are aerobic monophasic aqueous media.
- blood culture the fungal blood culture
- a blood sample whole blood or plasma
- a nutritive multiplication and / or filamentation medium Generally such a medium is Sabouraud medium or trypticase-soy medium, supplemented with SPS, EDTA or sodium citrate.
- SPS swine serum
- EDTA EDTA sodium citrate
- the duration of the step (1 °) is generally less than or equal to 48 h at a temperature between 25 and 40 e C, preferably 37 e C, when said step (I e ) is carried out.
- the multiplication medium of step (I e ) will advantageously be an aerobic aqueous medium.
- said nutritive medium for multiplying BL may advantageously comprise a substance, which (i) does not affect the growth of yeasts, (ii) is inert with respect to of the affinity of the filamentary forms for substance (F), and (iii) lysis of erythrocytes, leukocytes and macrophages to release the vitamins and growth factors contained in said erythrocytes, on the one hand, and for release any yeasts that fix or immobilize said leukocytes and macrophages, on the other hand.
- lysing substances of this type which are suitable, mention may in particular be made of detergents such as saponin.
- saponin this substance occurs at a concentration of 0.1 to 12 g / 1 (preferably 0.2-0.4 g / 1) in the nutrient medium.
- the preferred anticoagulant is heparin.
- Sodium citrate and EDTA are not suitable as anticoagulant means, in the sense that they are capable of inhibiting the development of filamentary forms.
- step (2 e ) is the filamentation of the BLs to obtain the filamentary forms.
- the filamentation of step (2 e ) is carried out for a period of at least 1 hour at 25-40 "C to obtain the filamentary forms chosen from the group comprising the germinative forms and filamentous forms in the case of yeast strains which filament, or blastospore-spherule forms in the case of yeast strains which give rise to pseudofilamentation.
- nutrient media which are suitable for carrying out the filamentation of step (2 e ), there are may in particular cite synthetic blastesis media and in particular those conventionally used for the identification of isolated strains of Candida.
- the nutritive multiplication medium may contain, in particular in the context of a blood culture:
- an anticoagulant agent preferably heparin
- the bringing into contact of step (3 e ) is an incubation for at least 0.5 h at 37 e C of the filamentary forms with said substance (F) previously fixed on an inert support.
- the duration of the step (3 e ) will generally be between 0.5 h and 4 h at 37 "C and advantageously between 1 h and 3 h at 37 e C. In practice, a duration of 1 h to 37 ° C will be sufficient for most of the yeast strains to be tested which filament, and a period of 1 to 3 h at 37 ° C will be used for the strains which give a pseudofilamentation such as Candida glabrata.
- the substance (F) intervening at step (3 e ) is chosen from fibrinogen and its derivatives (Fn, D, E, FDP, in particular FgDP and FnDP).
- step (4 e ) comprises a reading operation chosen from the group consisting of:
- Solution II is an effective technique for determining affinity according to the invention.
- Observation (b) implements the agglutination of a filamentary-F-support complex and preferably the complex
- GT-FDP-latex Depending on the choice of latex, the determination can be either qualitative or quantitative. With latex beads having a diameter greater than 1 micrometer and on which the substance (F) is fixed, a qualitative agglutination is obtained. With submicron latex beads having a diameter of less than 1 micrometer and on which the substance (F) is fixed [preferably the latex beads described in the international PCT application published WO-A-90/08 321] a quantitative agglutination is obtained. According to technical solution II, there is qualitatively observed (i) agglutination on the macroscopic scale only with the naked eye, or (ii) agglutination on the microscopic scale by measuring the variation in OD. When the support consists of latex beads, it acts as a means "amplifying" the result of the agglutination reaction.
- Solution III is a technique also effective for determining the affinity according to the invention. It is based on an enzymatic mechanism.
- observation (c) implements the use of an enzyme substrate specific for enzymes having leucine activity.
- arylamidase By "enzyme having leucine-arylamidase activity” is meant the enzymes which cleave into -L-Leu-OH and HR, the amino acid, dipeptide, tripeptide or tetrapeptide substrates ending at the CO end -terminal by a remainder
- Leu is the leucyl residue of the CO-terminal end and R is pNA or a chromogenic group analogous to pNA, such as the p-nitroanilino residues comprising a substituent on the phenyl nucleus (in particular Cl, Br , F, CH or OCH 3 ) and described in EP-A-0 110 306.
- the enzymes having such a leucine-aryla idase activity are enzymes characteristic of yeasts found in particular in filamentary forms.
- the enzyme substrate that is preferred according to
- 1'invention is an amino acid substrate, namely: H-L-Leu-pNA.
- the method of determination by enzymatic route comprises the stages consisting of - using an appropriate support (in particular a microplate for titration or a set of cuvettes),
- the affinity F / filamentary forms is manifested only for the yeast strains which are pathogenic.
- the affinity Global FgDP / GT or Global FnDP / GT is a quick, efficient and reliable way to determine whether or not yeast strains to be tested are pathogenic.
- a method is recommended for determining the pathogenic or non-pathogenic character of yeast strains to be tested, characterized in that it comprises
- the multiplication of blastos ⁇ pores in step (I e ) and / or the filamentation of said blastospores in step (2 e ) by blood culture are carried out in a liquid medium, preferably aerobic, from a blood or plasma sample containing yeast strains to be tested and previously diluted according to a dilution of x _x where x is a number greater than or equal to 50, to essentially eliminate any interference with other substances contained in the blood or plasma and which may interfere in the adhesion mechanism of said substance (F) on said yeasts, the interfering substances being capable of comprising in particular Fg, Fn, FgDP and FnDP, on the one hand, and the inflammation proteins, the anti-fungal compounds which may have been administered, anti antibodies (Candidate, on the other hand.
- a liquid medium preferably aerobic
- the technical solution recommended by the invention is particularly well suited to determining the pathogenic or non-pathogenic character of the yeast strains which filament to give GT, PMy and My.
- the blastospores contained in a sample of yeast strains to be tested are multiplied, in particular a sample of whole blood or blood plasma, in a BL multiplication medium which is aqueous, aerobic and constituted by a Shadomy medium enriched in yeast extract (where said yeast extract is at a concentration of 1 to 4 g / 1) and supplemented with saponin (0.2-0.4 g / 1), heparin, urea and, where appropriate, means antibacterial, for a period less or equal to 48 h at 37 e C and at pH 7.0-7.5, the plasma or blood sample is diluted by means of said multiplication medium to a x dilution -1 (where x is a number greater than or equal to 50), so as to obtain a population greater than or equal to 10 5 yeasts / ml.
- a BL multiplication medium which is aqueous, aerobic and constituted by a Shadomy medium enriched in yeast extract (where said yeast extract is at a concentration of 1 to 4
- the blastospores obtained according to step (I e ) or its aforementioned variant are filamented, in an aerobic aqueous medium constituted by the non-enriched and non-supplemented Shadomy medium, for 1-4 h at 37 e C and at pH 7.0-7.5, so as to obtain a sufficient volume of GT.
- Stage (3 )
- step (2 e ) A sample of the medium containing GT obtained at the end of step (2 e ) is incubated with a reagent (FDP-latex) consisting of latex beads coated with global FDP (global FgDP or global FnDP), during minus 1 h at 37 ° C and pH 7.0-7.5. Step (4 e ) The formation of the resulting complex is observed
- Examples 1 to 5 relate to tests in a so-called purified system
- Examples 6 to 9 relate to tests in the plasma system (whole blood or plasma).
- the incubate is taken at different times and placed in the presence, for 2 h at 37 "C, of fibrin covalently attached to a microtiter plate so as to study the affinity of the yeasts for fibrin.
- 199 IP is not an appropriate filament medium, as demonstrated below.
- Yeast forms OD incubation time (at 37 "C (at 405 nm) and at pH 7.0-7.5)
- rare neopeptone rare budding BL forms rare GT
- Fg and its derivatives were evaluated with respect to the filamentary forms of various yeasts, according to the operating methods described in Example 3 above, in function of the inoculum.
- the BLs of various strains of reference yeast (from recognized collections) and isolates (from clinical samples) are multiplied in an aerobic aqueous medium consisting of enriched Shadomy medium (yeast extract at 2 g / 1) and supplemented with urea (2 g / 1), saponin (0.2 g / 1), heparin and ampicillin, for 18 h at 37 "C and at pH 7.0-7.5; filamentation of the blastospores thus obtained, in an aerobic aqueous medium constituted by the normal Shadomy medium, for 1-4 h at 37 "C and at pH 7.0-7.5, to obtain the GT forms (or their analogs blastospores- spherules), strains subjected to filamentation (or pseudofilamentation) having a popula- tion of 10 5 to 10 6 yeasts / ml.
- enriched Shadomy medium enriched Shadomy medium
- saponin 0.2 g / 1
- heparin and ampicillin for 18 h
- resulting filamentation medium which contains GT (or analogs thereof called) to wells of microtiter plates coated with covalently Fg, then allowed to incubate for 1-3 h at 37 e C. then assesses affinity revealed by the HL-Leu-pNA substrate by the variation of OD at 405 nm.
- the results obtained are recorded in Tables Va (reference strains) and Vb (isolate strains) below.
- Candida albicans 2 Candida albicans 0 Candida tropicalis 0
- Candida kr ⁇ isei 1 Candida krusei 0
- Candida glabrata 1 Candida glabrata 0
- Candida parapsilosis 0
- Rhodotorula 1
- Rhodotorula 0
- Trichosporum 1
- Cryptococcus 1
- Cryptococcus 0
- Saccharomyces 0
- the plasma sample blood plasma or whole blood
- an anti-coagulant means in the minute following the blood test, then diluted then by means of enriched Shadomy medium (yeast extract 2 g / 1) and supplemented with saponin (10 g / 1), urea (2 g / 1) and ampicillin.
- filamentai ⁇ res essentially consist here of GT was contacted samples of filamentation medium (as obtained after culturing for 4 hours at 37 e C and pH 7 7,0-, 5) with the FDP-latex reagent of Example 6 for 1 h at 37 "C and at pH 7.0-7.5.
- affinity is not brought to the fore for the yeast forms themselves, that is to say the blastospores.
- affinity is specific for the filamentary forms of the yeasts tested and more mainly the GTs of said yeasts.
- the filamentary forms are covered by the FDP-latex reagent (adhesion of said reagent)
- Candida strains are recorded in Table VIII below. It is noted, as in Example 7, that the affinity is not demonstrated for the yeast forms properly speaking. say, that is to say the blastospores. On the other hand, the affinity is specific for the fila ⁇ mentary forms of the yeasts tested and more mainly the GTs of said yeasts. The advantage of separating the multiplication stage (if necessary) from the filamentation stage is also confirmed. TABLE VIII Influence of the concentration of yeasts
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Toxicology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9110523A FR2680519B1 (fr) | 1991-08-22 | 1991-08-22 | Procede pour mettre en evidence l'affinite du fibrinogene et de ses derives aux formes filamentaires de levures, utilisation dans le domaine de la determination des levures pathogenes notamment en hemoculture. |
DE69311140T DE69311140T2 (de) | 1991-08-22 | 1993-02-24 | Verfahren zur bestimmung der affinität von fibrinogen und seiner derivate gegenüber filamentären formen von hefen, und verwendung auf dem gebiet der bestimmung von pathogenen hefen insbesondere in blutkultur |
EP93905419A EP0686264B1 (fr) | 1991-08-22 | 1993-02-24 | Procede pour mettre en evidence l'affinite du fibrinogene et de ses derives aux formes filamentaires de levures, utilisation dans le domaine de la determination des levures pathogenes notamment en hemoculture |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9110523A FR2680519B1 (fr) | 1991-08-22 | 1991-08-22 | Procede pour mettre en evidence l'affinite du fibrinogene et de ses derives aux formes filamentaires de levures, utilisation dans le domaine de la determination des levures pathogenes notamment en hemoculture. |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994019696A1 true WO1994019696A1 (fr) | 1994-09-01 |
Family
ID=1340484
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1993/000180 WO1994019696A1 (fr) | 1991-08-22 | 1993-02-24 | Procede pour mettre en evidence l'affinite du fibrinogene et de ses derives aux formes filamentaires de levures, utilisation dans le domaine de la determination des levures pathogenes notamment en hemoculture |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0686264B1 (fr) |
DE (1) | DE69311140T2 (fr) |
FR (1) | FR2680519B1 (fr) |
WO (1) | WO1994019696A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2680519B1 (fr) * | 1991-08-22 | 1993-11-05 | Diagnostica Stago | Procede pour mettre en evidence l'affinite du fibrinogene et de ses derives aux formes filamentaires de levures, utilisation dans le domaine de la determination des levures pathogenes notamment en hemoculture. |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2190424A1 (fr) * | 1972-07-04 | 1974-02-01 | Ajinomoto Kk | |
WO1990008321A1 (fr) * | 1989-01-20 | 1990-07-26 | Diagnostica Stago | Particules sumicroniques, preparation et utilisation dans l'immunodiagnostic |
WO1991014787A1 (fr) * | 1990-03-23 | 1991-10-03 | Serbio | Procede d'identification de candida au moyen de substrats chromogenes |
FR2680519A1 (fr) * | 1991-08-22 | 1993-02-26 | Stago Diagnostica | Procede pour mettre en evidence l'affinite du fibrinogene et de ses derives aux formes filamentaires de levures, utilisation dans le domaine de la determination des levures pathogenes notamment en hemoculture. |
-
1991
- 1991-08-22 FR FR9110523A patent/FR2680519B1/fr not_active Expired - Fee Related
-
1993
- 1993-02-24 EP EP93905419A patent/EP0686264B1/fr not_active Expired - Lifetime
- 1993-02-24 WO PCT/FR1993/000180 patent/WO1994019696A1/fr active IP Right Grant
- 1993-02-24 DE DE69311140T patent/DE69311140T2/de not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2190424A1 (fr) * | 1972-07-04 | 1974-02-01 | Ajinomoto Kk | |
WO1990008321A1 (fr) * | 1989-01-20 | 1990-07-26 | Diagnostica Stago | Particules sumicroniques, preparation et utilisation dans l'immunodiagnostic |
WO1991014787A1 (fr) * | 1990-03-23 | 1991-10-03 | Serbio | Procede d'identification de candida au moyen de substrats chromogenes |
FR2680519A1 (fr) * | 1991-08-22 | 1993-02-26 | Stago Diagnostica | Procede pour mettre en evidence l'affinite du fibrinogene et de ses derives aux formes filamentaires de levures, utilisation dans le domaine de la determination des levures pathogenes notamment en hemoculture. |
Non-Patent Citations (6)
Title |
---|
ANN. INST. PASTEUR/MICROBIOL., vol. 138, no. 2, 1987, pages 177 - 187 * |
CHEMICAL ABSTRACTS, vol. 106, no. 21, 25 May 1987, Columbus, Ohio, US; abstract no. 173914, A. BOUALI ET AL.: "Characterization of binding of human fibrinogen to the surface of germ-tubes and mycelium of Candida albicans." page 513; column 2; * |
CHEMICAL ABSTRACTS, vol. 107, no. 11, 14 September 1987, Columbus, Ohio, US; abstract no. 93396, G. TRONCHIN ET AL.: "Immunocytochemical localization of the in vitro binding of human fibrinogen to Candida albicans germ tube and mycelium." page 404; column 1; * |
CHEMICAL ABSTRACTS, vol. 108, no. 3, 18 January 1988, Columbus, Ohio, US; abstract no. 19126, V. ANNAIX ET AL.: "Fibrinogen binding on Candida albicans germ tubes and mycelium" page 342; column 2; * |
J. GEN. MICROBIOL., vol. 133, no. 3, 1987, pages 545 - 551 * |
PROTIDES BIOL. FLUIDS, vol. 35, 1987, pages 399 - 402 * |
Also Published As
Publication number | Publication date |
---|---|
FR2680519B1 (fr) | 1993-11-05 |
EP0686264B1 (fr) | 1997-05-28 |
EP0686264A1 (fr) | 1995-12-13 |
DE69311140D1 (de) | 1997-07-03 |
FR2680519A1 (fr) | 1993-02-26 |
DE69311140T2 (de) | 1997-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1546366B1 (fr) | Procede de detection et de comptage de microorganismes dans un echantillon | |
WO2003025207A1 (fr) | Dispositif et procede de concentration et de detection de germes pathogenes a partir de produits sanguins et/ou de leurs derives | |
FR2926560A1 (fr) | Procede d'extraction et de purification d'acides nucleiques sur membrane | |
EP0333560B1 (fr) | Procédé de détermination quantitative de micro-organismes | |
EP1608769B1 (fr) | Procede et dispositif de detection et/ou d'identification de bacteries presentes dans un echantillon | |
EP0686264B1 (fr) | Procede pour mettre en evidence l'affinite du fibrinogene et de ses derives aux formes filamentaires de levures, utilisation dans le domaine de la determination des levures pathogenes notamment en hemoculture | |
FR2915208A1 (fr) | Composition comprenant l'association d'edta et de pei pour augmenter la permeabilite des parois des microorganismes et utilisations de ladite composition | |
WO1998055861A1 (fr) | Procede de numeration de cellules viables | |
EP2005181B1 (fr) | Standard c4d / c4b pour cytometrie de flux quantitative du rejet humoral de transplantation | |
CA1335704C (fr) | Procede de numeration, de depistage et d'identification des mycoplasmes en general et urogenitaux en particulier et milieu biologique specialement adapte a cet effet | |
EP2252700B1 (fr) | Procede de detection en temps reel de microorganismes dans un milieu de culture liquide par lyse cellulaire | |
EP0468946B1 (fr) | Procédé enzymatique pour la détermination d'antibiotiques à noyau beta-lactame | |
EP3942034A1 (fr) | Billes de verre fonctionnalisees, leur utilisation pour capter des micro-organismes et les dispositifs correspondants | |
FR2894984A1 (fr) | Composition pour augmenter la permeabilite des parois microorganismes et procede de detection sur membrane desdits microorganismes. | |
EP0159223B1 (fr) | Réactifs et nécessaires pour le dosage quantitatif d'un acide nucléique viral dans un milieu biologique et procédé de dosage de cet acide nucléique viral | |
WO2010092266A2 (fr) | Amplification génique statistique pour l'identification sans a priori de micro-organismes par séquençage sans étape de clonage | |
EP4052014A1 (fr) | Dispositif contenant des billes de verre fonctionnalisees avec du polyethyleneimine, et leur utilisation pour capter les micro-organismes | |
EP0288388B1 (fr) | Immunodiagnostic des parasitoses dues à un protozoaire chez les mollusques | |
EP4151749A1 (fr) | Oligonucléotide à double structure tige-boucle et utilisation dans la détection d'analytes d'intérêt | |
CA2713411C (fr) | Procede de detection et/ou de quantification et/ou d'identification in vitro de composes infectieux dans un materiau biologique | |
WO1995011991A1 (fr) | SONDE ET PROCEDE DE DETECTION DES LEVURES DE L'ESPECE $i(CANDIDA KRUSEI) | |
FR2723204A1 (fr) | Procede de detection et/ou de dosage de compose(s) infectueux dans un materiau biologique et support utilise pour ledit procede | |
CA2713155A1 (fr) | Procede de detection et/ou de quantification et/ou d'identification in vitro de bacteries dans un materiau biologique | |
WO2004111263A1 (fr) | Milieu de culture pour la recherche des salmonelles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1993905419 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: US Ref document number: 1995 507332 Date of ref document: 19950823 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1993905419 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1993905419 Country of ref document: EP |